Quick summary: The US Food and Drug Administration has authorised the marketing of fruit flavoured electronic nicotine delivery systems for the first time, marking a significant regulatory pivot towards assessing reduced risk alternatives through a broader public health lens. Clinical data suggests that fruit flavours can substantially increase successful quit attempts and help adult smokers transition away from combustible cigarettes, though public health groups remain concerned about the potential appeal to younger demographics despite built in biometric age verification technologies. These landmark approvals carry major implications for public policy and healthcare practice, demonstrating that evidence led harm reduction strategies must balance accessibility for tobacco cessation with strict access controls to safeguard youth well being.
The US Food and Drug Administration has authorised the marketing of mango- and blueberry-flavoured electronic nicotine delivery systems for the first time, marking a notable change in its approach to alternative nicotine products.
The decision, announced on 5th May 2026, covers products from Los Angeles-based company Glas, including Gold mango and Sapphire blueberry flavour pods alongside menthol variants. All contain 50 mg/ml nicotine and are intended for adult smokers aged 21 and over.
The FDA emphasised that the authorisations do not constitute an endorsement of the products and that they are intended only for current adult smokers seeking to switch or quit.
Chris Allen, CEO of nicotine testing and regulatory consultancy Broughton, described the move as one of the most significant regulatory developments the sector has seen in recent years. While tobacco- and menthol-flavoured authorisations had already signalled a gradual shift in regulatory thinking, the approval of fruit-flavoured products suggests the agency is increasingly willing to assess reduced-risk nicotine products through a broader public health lens.
Central to the FDA’s assessment process is its Appropriate for the Protection of Public Health standard, which requires regulators to weigh the potential benefits for adult smokers against the risks associated with youth uptake. In draft guidance published in early 2026, the FDA acknowledged that non-tobacco-flavoured products may, in certain circumstances, support adult smokers in switching away from combustible cigarettes or increasing quit attempts.
This is supported by a longitudinal study published in the National Library of Medicine, which found that adult users of sweet- or fruit-flavoured nicotine vaping products were more likely to transition away from cigarette smoking than those using tobacco-flavoured alternatives.
The authorisations should not be interpreted as a relaxation of regulatory expectations. Manufacturers are now expected to integrate public health and compliance considerations into product development from the outset, fully characterising products from a toxicological perspective, understanding behavioural risk factors, and demonstrating that access controls are built into the product itself.
The approved Glas products incorporate advanced age-verification technologies such as ID scanning, app-linking, and biometrics to help restrict youth access.
Public health groups have nonetheless expressed concerns about the potential appeal of fruit flavours to younger users despite these safeguards.
The FDA’s decision may have implications beyond the US market. While regulatory approaches vary globally, it reflects a broader shift towards evidence-led discussions around harm reduction. The UK and other jurisdictions maintain strict rules on vaping flavours, seeking to protect young people while supporting adult smokers.
As Allen noted, the debate is increasingly moving away from whether reduced-risk products should exist at all, and towards how they can be appropriately regulated to maximise public health benefits while minimising unintended consequences. For manufacturers operating across multiple international markets, regulatory strategy can no longer be treated as a final-stage compliance exercise.